echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Efficacy and safety of adjuvant therapy for melanoma in clinical practice: clinical research and reality

    Eur J Cancer: Efficacy and safety of adjuvant therapy for melanoma in clinical practice: clinical research and reality

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Since 2011, the treatment pattern of metastatic melanoma has undergone tremendous changes


    Since 2011, the treatment pattern of metastatic melanoma has undergone tremendous changes


    During the study period, a total of 2199 patients were registered in the DMTR database


    During the study period, a total of 2199 patients were registered in the DMTR database


    In the entire study population, the 12-month relapse-free survival rate was 70.



     RFS

    In AJCC-7 stage IIIA patients, the 12-month recurrence-free survival rate was 87.


    In AJCC-7 stage IIIA patients, the 12-month recurrence-free survival rate was 87.



    Multivariate analysis of related factors

    The one-year follow-up group included 367 patients who were followed up for at least 12 months or died within 12 months


    The one-year follow-up group included 367 patients who were followed up for at least 12 months or died within 12 months




    224 patients (61.


    The 12-month RFS rate of patients in the 1-year follow-up group was 69.


    In summary, studies have shown that in daily practice, adjuvant anti-PD -1 treatment after resection of stage III/IV melanoma shows a slightly higher toxicity rate and more frequent premature discontinuation, but compared with clinical studies, RFS The rates are similar


    Original source:

    de Meza MM, Ismail RK, Rauwerdink D, et al.
    Adjuvant treatment for melanoma in clinical practice-Trial versus reality.
    Eur J Cancer.
    2021 Sep 29:S0959-8049(21)00575-X.
    doi: 10.
    1016/j.
    ejca .
    2021.
    08.
    044.
    Epub ahead of print.
    PMID: 34600790.

    de Meza MM, Ismail RK, Rauwerdink D, et al.
    Adjuvant treatment for melanoma in clinical practice-Trial versus reality.
    Eur J Cancer.
    2021 Sep 29:S0959-8049(21)00575-X.
    doi: 10.
    1016/j.
    ejca .
    2021.
    08.
    044.
    Epub ahead of print.
    PMID: 34600790.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.